Search Results

Experienced industry leader to head Complexa’s clinical development programs

Feb. 7, 2020 13:00 UTC Experienced industry leader to head Complexa’s corporate and business development programs BERWYN, Pa.--( BUSINESS WIRE )-- Complexa Inc. today announced the appointment of Elisabeth Leiderman, MD, MBA, as Chief Business Officer. Dr. Leiderman formerly served as Senior Vice President, Head of Corporate Development for Fortress Biotech where she led strategy and oversight for all aspects of corporate development for the company’s 10 subsidiaries.

Complexa Inc. today announced the completion of patient enrollment in the FIRSTx study, a Phase 2 clinical trial evaluating the safety and efficacy of the company’s lead candidate, CXA-10, to treat primary focal segmental glomerulosclerosis (FSGS).

Founder of Acerta Pharma to lead Complexa as it advances Phase 2 clinical development of lead compound CXA-10 in two orphan indications

Complexa Inc. announced dosing of the first patient in PRIMEx, a Phase 2 clinical trial evaluating the safety and efficacy of two doses of the company’s lead candidate, CXA-10, to treat pulmonary arterial hypertension.

FSGS is a rare and severe form of kidney disease that can lead to permanent kidney damage and even kidney failure.